You are here: Industry Insights > Eisai

News List

First Alzheimer's drug from Eisai/UCL alliance to enter clinical trials pharmatimes
December 07, 2018
The first drug candidate from Eisai and University College London (UCL)’s drug discovery collaboration is to enter Phase I clinical trials for Alzheimer’s disease (AD) early next year.
EISAI launches Lenvima in China biospectrumasia
November 19, 2018
In addition to China, LENVIMA is approved for use in the treatment of HCC in Japan, the United States, Europe, and other
EISAI launches Lenvima in China biospectrum
November 13, 2018
In addition to China, LENVIMA is approved for use in the treatment of HCC in Japan, the United States, Europe, and other countries in Asia and around the world
Lenvima backed for NHS use to treat liver cancer pharmatimes
November 12, 2018
The Institute has issued a final appraisal document (FAD) recommending the use of Lenvima (lenvatinib) for untreated, advanced, unresectable hepatocellular carcinoma (HCC)
Eisai announces Data from the Phase II Clinical Trial of BAN2401 biospectrumasia
October 29, 2018
Clinical Study 201 is a placebo-controlled, double-blind, parallel-group, randomized study in 856 patients with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) with confirmed amyloid pathology in the brain
Eisai discovers new compound to treat Parkinson's disease biospectrumasia
October 22, 2018
Researchers has identified a compound that has the potential to be a treatment for Parkinson's disease by using dopaminergic neurons differentiated from induced pluripotent stem (iPS) cells from patients with familial Parkinson's disease.
Eisai's Lenvima gets nod in China for liver cancer treatment biospectrumasia
September 07, 2018
HBV is considered to be a negative predictor of tumor response to existing drug therapies.
Eisai announces long-term cardiovascular outcomes data for anti-obesity Agent biospectrumasia
August 29, 2018
CAMELLIA-TIMI 61, conducted in collaboration with the Thrombolysis in Myocardial Infarction (TIMI) Study Group of Brigham and Women's Hospital, was a 12,000 patient study of BELVIQ at over 400 sites in eight countries.
Study shows Eisai's obesity drug Belviq does not increase major cardiovascular events firstwordpharma
August 29, 2018
Study results presented at the European Society of Cardiology (ESC) congress showed that in a high-risk population of overweight or obese patients, Eisai's Belviq (lorcaserin) was associated with sustained weight loss without a higher rate of major cardio
Eisai gets marketing approval from EC for LENVIMA biospectrumasia
August 24, 2018
As First-Line Treatment in Adults with Advanced or Unresectable Hepatocellular Carcinoma

Previous page 1 2 3 4 5 6 7 8 9 10 Next page